Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports
$16,500.00   |  '

Parkinson’s Disease Dementia | Executive Insights | US | 2019

Login to access report north_east
Buy report north_east

Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia. PD dementia is progressive and severely impacts QOL and independence, and most expert neurologists interviewed by DRG cite dementia as having the greatest unmet need for new therapeutics among all PD nonmotor symptoms. Available antidementia agents (mostly prescribed off-label) are largely ineffective. Opportunity for premium pricing and limited competition has recently spurred industry activity in this arena and a number of novel agents are in early-phase development. Understanding current management strategies, prevailing market access factors, and the market outlook for PD dementia is crucial for developers advancing new drugs for this understudied and underdeveloped market space.

Questions Answered

  • What are the key areas of unmet need and opportunity in the PD dementia market?
  • What are the key drivers and limiters of the PD dementia market?
  • How does each player influence the market, and how will this change in the future?
  • What is the expected impact of novel therapy launches, and how might they impact opportunities in the PD dementia market?

Geography: United States

Primary research: 6 KOL interviews in Q1 2019

Key companies covered: Adamas, Allergan, Alkahest, Anavex, Eli Lilly, IRLAB

Key drugs covered: Rivastigmine, donepezil, galantamine, memantine, Namzaric, GRF6019/6021, ANAVEX 2-73, LY3154207, IRL752

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
north_east
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD) resulting from insufficient erythropoietin production by impaired kidneys. The primary goal of renal anemia treatment is to…
north_east
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east